Noninvasive quantification of solid tumor microstructure using VERDICT MRI.
There is a need for biomarkers that are useful for noninvasive imaging of tumor pathophysiology and drug efficacy. Through its use of endogenous water, diffusion-weighted MRI (DW-MRI) can be used to probe local tissue architecture and structure. However, most DW-MRI studies of cancer tissues have relied on simplistic mathematical models, such as apparent diffusion coefficient (ADC) or intravoxel incoherent motion (IVIM) models, which produce equivocal results on the relation of the model parameter estimate with the underlying tissue microstructure. Here, we present a novel technique called VERDICT (Vascular, Extracellular and Restricted Diffusion for Cytometry in Tumors) to quantify and map histologic features of tumors in vivo. VERDICT couples DW-MRI to a mathematical model of tumor tissue to access features such as cell size, vascular volume fraction, intra- and extracellular volume fractions, and pseudo-diffusivity associated with blood flow. To illustrate VERDICT, we used two tumor xenograft models of colorectal cancer with different cellular and vascular phenotypes. Our experiments visualized known differences in the tissue microstructure of each model and the significant decrease in cell volume resulting from administration of the cytotoxic drug gemcitabine, reflecting the apoptotic volume decrease. In contrast, the standard ADC and IVIM models failed to detect either of these differences. Our results illustrate the superior features of VERDICT for cancer imaging, establishing it as a noninvasive method to monitor and stratify treatment responses.
Authors' Affiliations: Department of Computer Science, Centre for Medical Image Computing; Division of Medicine, Centre for Advanced Biomedical Imaging; UCL Cancer Institute, University College London, London, United Kingdom.
Eletheria
E
Panagiotaki
Simon
S
Walker-Samuel
Bernard
B
Siow
S Peter
SP
Johnson
Vineeth
V
Rajkumar
R Barbara
RB
Pedley
Mark F
MF
Lythgoe
Daniel C
DC
Alexander
D000818:Animals; D045744:Cell Line, Tumor; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D038524:Diffusion Magnetic Resonance Imaging / Q000379:methods*; D005260:Female; D006801:Humans; D051379:Mice; D008962:Models, Theoretical; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000648:ultrastructure*; D000093542:Gemcitabine
D003841:Deoxycytidine; D000093542:Gemcitabine